Original Article

Efficacy of Combination Therapy With Pirfenidone and Low-Dose Cyclophosphamide for Refractory Interstitial Lung Disease Associated With Connective Tissue Disease: A Case-Series of Seven Patients

Volume 35 · Issue 2 Publish Date: June 30, 2020
Full Text PDF HTML
DOI
Lichong SHEN ORCID
Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai China image/svg+xml
Qingran YAN ORCID
Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai China image/svg+xml
Xiaoxiang CHEN ORCID
Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai China image/svg+xml
Lichong SHEN, Qingran YAN, & Xiaoxiang CHEN. (2020). Efficacy of Combination Therapy With Pirfenidone and Low-Dose Cyclophosphamide for Refractory Interstitial Lung Disease Associated With Connective Tissue Disease: A Case-Series of Seven Patients. Archives of Rheumatology, 35(2), 180–188. https://doi.org/10.46497/ArchRheumatol.2020.7381
Full Text PDF HTML

Abstract

Objectives: This study reports a low dose combination therapy of cyclophosphamide (CYC) and pirfenidone (PFD) and the efficiency and safety of the therapy in refractory connective tissue disease associated interstitial lung disease (CTD-ILD) patients.

Patients and methods: The study included seven CTD-ILD patients (2 males, 5 females; mean age 48.8 years; range, 32 to 63 years) treated between January 2016 and December 2017 in our clinic. At enrolment, all patients had shown no improvement in their symptoms (dyspnea or cough) after at least one month of high dose steroids treatment. Patients who had received adjusted immunosuppressive agents other than steroids or anti-fibrotic medications within the three months before enrolment were excluded. We changed the treatment to a low dose combination of CYC 0.4 g/m2 monthly and PFD 300 mg twice per day and quickly reduced the steroids. All the patients were followed-up for 12 months.

Results: Two patients had anti-synthetase syndrome, two had Sjögren syndrome, two had scleroderma and one had mixed connective tissue disease. The baseline forced vital capacity (FVC) was 39-81% and the six-minute walk distance (6MWD) was 202 m-324 m. Within 12 months follow-up, the median improvement in the FVC was 13.4% (range, 0-35.9%), the median improvement of carbon monoxide diffusing capacity was 6.3% (range, 1.7-16%) and the median improvement of 6MWD was 52.7% (range, 34.4-86.3%). All the patients were self-sufficient, and their dyspnea, chest high- resolution computed tomography scores, and quality of life improved simultaneously. Exceeding our expectations, no adverse events associated with CYC or PFD were observed during the follow-up period.

Conclusion: Our study provided preliminary while promising clinical evidence for combination therapy of CYC-PFD for CTD-ILD. A low dose combination of CYC and PFD was unexpectedly well tolerated, with satisfactory effects in refractory CTD-ILD patients. Well-designed controlled studies are needed to further establish the safety and efficacy of this approach.

Similar Articles

Article Info
Published In
Journal Archives of Rheumatology
Volume / Issue Volume 35 · Issue 2
Pages 180-188
History
Published Online June 30, 2020
License
Affiliations
Lichong SHEN ORCID
Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai China
Qingran YAN ORCID
Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai China
Xiaoxiang CHEN ORCID
Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai China
Cite this Article
Lichong SHEN, Qingran YAN, & Xiaoxiang CHEN. (2020). Efficacy of Combination Therapy With Pirfenidone and Low-Dose Cyclophosphamide for Refractory Interstitial Lung Disease Associated With Connective Tissue Disease: A Case-Series of Seven Patients. Archives of Rheumatology, 35(2), 180–188. https://doi.org/10.46497/ArchRheumatol.2020.7381
Share
Outlines